Dazodalibep hit its phase 3 primary endpoint at week 48, building on phase 2 data showing a 6.3-point ESSDAI reduction versus placebo.
|Articles|April 13, 2018
Catalent Adds Clinical Supplies Capacity
Author(s)BioPharm International Editors
A $5.5-million expansion at its Philadelphia, PA clinical supplies facility gives Catalent additional packaging and storage capacity.
Advertisement
Catalent Pharma Solutions has completed a $5.5-million-expansion program at its 200,000-sq.-ft. site in Philadelphia, PA, to provide additional clinical packaging and storage capacity. The facility is one of the largest sites in Catalent’s global clinical supply network, the company reported in an April 12, 2018 announcement.
The investment adds 40% more pallet space for refrigerated and ambient clinical storage, additional cold chain packaging areas, and a clinical label control area. The building also features a campus-wide environmental monitoring and building management system.
“The expansion not only allows us to meet the demand for additional capacity to serve large-scale clinical studies today, but also provides the space necessary for future growth,” said Albert Quintero, general manager, Clinical Supply Services.
Source:
Advertisement
Related to this article
Eron Kelly, CEO of ConcertAI, and Dr. Shaalan Beg, CMO, oncology, ConcertAI, discuss how AI can help physicians access the right information at the right time while supporting clinical trials, research, and quality initiatives.
Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
Novo Nordisk reports that CagriSema outperformed tirzepatide with 12.4% weight loss versus 9.1% in a phase 3 trial in adults with type 2 diabetes.
New data show risk-based and centralized monitoring shifts effort across roles, sites, and timelines, reshaping how sponsors plan CRA capacity needs.
Laru-zova helped 31% of high-dose patients gain 15+ letters of vision, representing the first pivotal trial to succeed in treating XLRP.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement